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Type 2 diabetes (T2D) can be prevented in pre-diabetic individuals with impaired glucose tolerance
(IGT). Here, we have used a metabolomics approach to identify candidate biomarkers of pre-diabetes.
We quantified 140 metabolites for 4297 fasting serum samples in the population-based Cooperative
Health Research in the Region of Augsburg (KORA) cohort. Our study revealed significant metabolic
variation in pre-diabetic individuals that are distinct from known diabetes risk indicators, such as
glycosylated hemoglobin levels, fasting glucose and insulin. We identified three metabolites (glycine,
lysophosphatidylcholine (LPC) (18:2) and acetylcarnitine) that had significantly altered levels in IGT
individuals as compared to thosewithnormal glucose tolerance,withP-values ranging from2.410 4
to 2.11013. Lower levels of glycine and LPCwere found to be predictors not only for IGT but also for
T2D, and were independently confirmed in the European Prospective Investigation into Cancer and
Nutrition (EPIC)-Potsdam cohort. Using metabolite–protein network analysis, we identified seven
T2D-related genes that are associatedwith these three IGT-specificmetabolites bymultiple interactions
with four enzymes. The expression levels of these enzymes correlate with changes in the metabolite
concentrations linked to diabetes. Our results may help developing novel strategies to prevent T2D.
Molecular Systems Biology 8: 615; published online 25 September 2012; doi:10.1038/msb.2012.43
Subject Categories: metabolic and regulatory networks; molecular biology of disease
Keywords: early diagnostic biomarkers; IGT; metabolomics; prediction; T2D
Introduction
Type 2 diabetes (T2D) is defined by increased blood glucose
levels due to pancreatic b-cell dysfunction and insulin
resistance without evidence for specific causes, such as
autoimmune destruction of pancreatic b-cells (Krebs et al,
2002; Stumvoll et al, 2005; Muoio and Newgard, 2008). A state
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of pre-diabetes (i.e., impaired fasting glucose (IFG) and/or
impaired glucose tolerance (IGT)) with only slightly elevated
blood glucose levels may precede T2D for years (McGarry,
2002; Tabak et al, 2012). The development of diabetes in pre-
diabetic individuals can be prevented or delayed by dietary
changes and increased physical activity (Tuomilehto et al,
2001; Knowler et al, 2002). However, no specific biomarkers
that enable prevention have been reported.
Metabolomics studies allowmetabolites involved in disease
mechanisms to be discovered by monitoring metabolite level
changes in predisposed individuals compared with healthy
ones (Shaham et al, 2008; Newgard et al, 2009; Zhao et al,
2010; Pietilainen et al, 2011; Rhee et al, 2011; Wang et al, 2011;
Cheng et al, 2012; Goek et al, 2012). Altered metabolite levels
may serve as diagnostic biomarkers and enable preventive
action. Previous cross-sectional metabolomics studies of T2D
were either based on small sample sizes (Shaham et al, 2008;
Wopereis et al, 2009; Zhao et al, 2010; Pietilainen et al, 2011) or
did not consider the influence of common risk factors of T2D
(Newgard et al, 2009). Recently, based on prospective
nested case–control studies with relative large samples (Rhee
et al, 2011; Wang et al, 2011), five branched-chain and
aromatic amino acids were identified as predictors of T2D
(Wang et al, 2011). Here, using various comprehensive large-
scale approaches, we measured metabolite concentration
profiles (Yu et al, 2012) in the population-based (Holle et al,
2005; Wichmann et al, 2005) Cooperative Health Research
in the Region of Augsburg (KORA) baseline (survey 4 (S4))
and follow-up (F4) studies (Rathmann et al, 2009; Meisinger
et al, 2010; Jourdan et al, 2012). The results of these cross-
sectional and prospective studies allowed us to (i) reliably
identify candidate biomarkers of pre-diabetes and (ii) build
metabolite–protein networks to understand diabetes-related
metabolic pathways.
Results
Study participants
Individuals with known T2D were identified by physician-
validated self-reporting (Rathmann et al, 2010) and excluded
from our analysis, to avoid potential influence from anti-
diabetic medication with non-fasting participants and indivi-
duals with missing values (Figure 1A). Based on both fasting
and 2-h glucose values (i.e., 2 h post oral 75 g glucose load),
individuals were defined according to the WHO diagnostic
criteria to have normal glucose tolerance (NGT), isolated IFG
(i-IFG), IGT or newly diagnosed T2D (dT2D) (WHO, 1999;
Rathmann et al, 2009; Meisinger et al, 2010; Supplementary
Table S1). The sample sets include 91 dT2D patients and 1206
individuals with non-T2D, including 866 participants with
NGT, 102 with i-IFG and 238 with IGT, in the cross-sectional
KORA S4 (Figure 1A; study characteristics are shown in
Table I). Of the 1010 individuals in a fasting state who
participated at baseline and follow-up surveys (Figure 1B,
study characteristics of the KORA F4 survey are shown in
Supplementary Table S2), 876 of them were non-diabetic at
baseline. Out of these, about 10% developed T2D (i.e., 91
incident T2D) (Figure 1C). From the 641 individuals with NGT
at baseline, 18% developed IGT (i.e., 118 incident IGT) 7 years
later (Figure 1D). The study characteristics of the prospective
KORA S4-F4 are shown in Table II.
Analyses strategies
We first screened for significantly differed metabolites
concentration among four groups (dT2D, IGT, i-IFG and
NGT) for 140 metabolites with cross-sectional studies in
KORA S4, and for 131 metabolites in KORA F4. Three IGT-
specific metabolites were identified and further investigated in
the prospective KORA S4-F4 cohort, to examine whether the
baseline metabolite concentrations can predict incident IGT
and T2D, and whether they are associated with glucose
tolerance 7 years later. Our results are based on a prospective
population-based cohort, which differed from previous nested
case–control study (Wang et al, 2011). We also performed
analysis with same study design using our data. The obtained
results provided clues to explain the differences between the
two sets of biomarkers. The three metabolites were also
replicated in an independent European Prospective Investiga-
tion into Cancer and Nutrition (EPIC)-Potsdam cohort. Finally,
the relevance of the identified metabolites was further
investigated with our bioinformatical analysis of protein-
metabolite interaction networks and gene expression data.
Identification of novel pre-diabetes metabolites
distinct from known T2D risk indicators
To identify metabolites with altered concentrations between
the individuals with NGT, i-IFG, IGT and dT2D, we first
examined five pairwise comparisons (i-IFG, IGT and dT2D
versus NGT, as well as dT2D versus either i-IFG or IGT) in the
cross-sectional KORA S4. Based on multivariate logistic
regression analysis, 26 metabolite concentrations differed
significantly (P-valueso3.610 4) between two groups in
at least one of the five comparisons (Figure 2A; odds ratios
(ORs) and P-values are shown in Table III). These associations
were independent of age, sex, bodymass index (BMI), physical
activity, alcohol intake, smoking, systolic blood pressure (BP)
and HDL cholesterol (model 1). As expected, the level of total
hexose H1, which is mainly represented by glucose (Pearson’s
correlation coefficient value r between H1 and fasting glucose
reached 0.85; Supplementary Table S3), was significantly
different in all five comparisons. The significantly changed
metabolite panel differed from NGT to i-IFG or to IGT. Most of
the significantly altered metabolite concentrations were found
between individuals with dT2D and IGT as compared with
NGT (Supplementary Table S4A).
To investigate whether HbA1c, fasting glucose and fasting
insulin levels mediate the shown associations, these were
added as covariates to the regression analysis (model 2) in
addition tomodel 1 (Figure 2B).We observed that, under these
conditions, no metabolite differed significantly when compar-
ing individuals with dT2D to those with NGT, suggesting
that these metabolites are associated with HbA1c, fasting
glucose and fasting insulin levels (r values are shown in
Supplementary Table S3). Only ninemetabolite concentrations
significantly differed between IGTandNGT individuals (Table III;
Supplementary Table S4B). These metabolites therefore
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represent novel biomarker candidates, and are independent
from the known risk indicators for T2D. The logistic regression
analysis was based on each single metabolite, and some of
these metabolites are expected to correlate with each other. To
further assess the metabolites as a group, we employed two
additional statistical methods (the non-parametric random
forest and the parametric stepwise selection) to identify
unique and independent biomarker candidates. Out of the
nine metabolites, five molecules (i.e., glycine, LPC (18:2), LPC
(17:0), LPC (18:1) and C2) were select after random forest, and
LPC (17:0) and LPC (18:1) were then removed after the
stepwise selection. Thus, three molecules were found to
contain independent information: glycine (adjusted OR¼ 0.67
(0.54–0.81), P¼ 8.610 5), LPC (18:2) (OR¼ 0.58 (0.46–
0.72), P¼ 2.110 6) and acetylcarnitine C2 (OR¼ 1.38
(1.16–1.64), P¼ 2.410 4) (Figure 2C). Similar results were
observed in the follow-up KORA F4 study (Supplementary
Figure S1). For instance, when 380 IGT individuals were
compared with 2134 NGT participants, these three metabolites
were also found to be highly significantly different (glycine,
OR¼ 0.64 (0.55–0.75), P¼ 9.310 8; LPC (18:2), OR¼ 0.47
(0.38–0.57), P¼ 2.11013; and C2, OR¼ 1.33 (1.17–1.49),
P¼ 4.910 6) (Supplementary Table S5).
Predict risks of IGT and T2D
To investigate the predictive value for IGTand T2D of the three
identified metabolites, we examined the associations between
baseline metabolite concentrations and incident IGT and T2D
Table I Characteristics of the KORA S4 cross-sectional study sample
Clinical and laboratory parameters NGT i-IFG IGT dT2D
N 866 102 238 91
Age (years) 63.5±5.5 64.1±5.2 65.2±5.2 65.9±5.4
Sex (female) (%) 52.2 30.4 44.9 41.8
BMI (kg/m2) 27.7±4.1 29.2±4 29.6±4.1 30.2±3.9
Physical activity (%41h per week) 46.7 35.3 39.9 36.3
Alcohol intakea (%) 20.2 20.5 25.2 24.2
Current smoker (%) 14.8 10.8 10.9 23.1
Systolic BP (mmHg) 131.7±18.9 138.9±17.9 140.7±19.8 146.8±21.5
HDL cholesterol (mg/dl) 60.5±16.4 55.7±15.9 55.7±15.1 50.0±15.8
LDL cholesterol (mg/dl) 154.5±39.8 152.1±37.7 155.2±38.6 146.1±44.6
Triglycerides (mg/dl) 120.7±68.3 145.0±96.0 146.6±80.0 170.6±107.1
HbA1c (%) 5.56±0.33 5.62±0.33 5.66±0.39 6.21±0.83
Fasting glucose (mg/dl) 95.6±7.1 114.2±3.7 104.5±9.7 133.2±31.7
2-h Glucose (mg/dl) 102.1±21.0 109.3±18.7 163.4±16.4 232.1±63.7
Fasting insulin (mU/ml) 10.48±7.28 16.26±9.67 13.92±9.53 17.70±12.61
NGT, normal glucose tolerance; i-IFG, isolated impaired fasting glucose; IGT, impaired glucose tolerance; dT2D, newly diagnosed type 2 diabetes; BP, blood pressure;
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Percentages of individuals or means±s.d. are given for each variable and each group (NGT, i-IFG, IGTand dT2D).
aX20 g/day for women;X40 g/day for men.
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Figure 1 Population description. Metabolomics screens in the KORA cohort, at baseline S4 (A), overlapped between S4 and F4 (B) and prospective (C, D). Participant
numbers are shown. Normal glucose tolerance (NGT), isolated impaired fasting glucose (i-IFG), impaired glucose tolerance (IGT), type 2 diabetes mellitus (T2D) and
newly diagnosed T2D (dT2D). Non-T2D individuals include NGT, i-IFG and IGT participants.
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using the prospective KORA S4-F4 cohort (Table II). We
compared baseline metabolite concentrations in 118 incident
IGT individuals with 471 NGT control individuals. We found
that glycine and LPC (18:2), but not C2, were significantly
different at the 5% level in both adjusted model 1 and model 2
(Table IV; Supplementary Table S6). Significant differences
were additionally observed for glycine and LPC (18:2), but not
for C2, at baseline concentrations between the 91 incident T2D
individuals and 785 participants who remained diabetes free
(non-T2D). Each standard deviation (s.d.) increment of the
combinations of the three metabolites was associated with a
33% decreased risk of future diabetes (OR¼ 0.39 (0.21–0.71),
P¼ 0.0002). Individuals in the fourth quartile of the combined
metabolite concentrations had a three-fold lower chance of
developing diabetes (OR¼ 0.33 (0.21–0.52), P¼ 1.810 5),
compared with those whose serum levels were in the first
quartile (i.e., combination of glycine, LPC (18:2) and C2),
indicating a protective effect from higher concentrations of
glycine and LPC (18:2) combined with a lower concentration
of C2. With the full adjusted model 2, consistent results were
obtained for LPC (18:2) but not for glycine (Supplementary
Table S6). When the three metabolites were added to the fully
Table II Characteristics of the KORA S4-F4 prospective study samples
NGTat baseline (n¼ 589) Non-T2D at baseline (n¼ 876)
Remained NGT
at follow-up
Developed IGT
at follow-up
Remained Non-T2D
at follow-up
Developed T2D
at follow-up
N 471 118 785 91
Age (years) 62.4±5.4 63.9±5.5 62.9±5.4 65.5±5.2
Sex (female) (%) 52.2 55.9 50.8 34.1
BMI (kg/m2) 27.2±3.8 28.2±3.9 27.9±4 30.2±3.6
Physical activity (%41h per week) 52.9 43.2 52.2 58.2
Alcohol intakea (%) 19.9 20.3 20.6 19.8
Smoker (%) 14.6 9.3 12.0 14.3
Systolic BP (mmHg) 129.6±18.2 134.2±18.7 132.4±18.6 137.8±19
HDL cholesterol (mg/dl) 61.3±16.8 58.9±16.2 60.0±16.5 51.9±12.4
LDL cholesterol (mg/dl) 153.9±38.4 156.9±42.7 154.5±39.5 157.7±41.6
Triglycerides (mg/dl) 118.1±63.9 129.5±79.0 125.0±70.0 151.2±74.2
HbA1c (%) 5.54±0.33 5.59±0.34 5.6±0.3 5.8±0.4
Fasting glucose (mg/dl) 94.7±6.9 96.6±7.1 97.7±8.8 106.1±10.1
2-h Glucose (mg/dl) 98.2±20.5 109.9±16.8 109.3±28 145.9±32.3
Fasting insulin (mU/ml) 9.91±6.48 11.79±8.83 11.0±7.6 16.2±9.6
BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Percentages of individuals or means±s.d. are given for each variable and each group.
aX20 g/day for women;X40 g/day for men.
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Figure 2 Differences in metabolite concentrations from cross-sectional analysis of KORA S4. Plots (A, B) show the names of metabolites with significantly different
concentrations in multivariate logistic regression analyses (after the Bonferroni correction for multiple testing with Po3.6 10 4) in the five pairwise comparisons of
model 1 and model 2. Plot (C) shows the average residues of the concentrations with standard errors of the three metabolites (glycine, LPC (18:2) and acetylcarnitine
C2) for the NGT, IGT and dT2D groups. Plot (A) shows the results with adjustment for model 1 (age, sex, BMI, physical activity, alcohol intake, smoking, systolic BP and
HDL cholesterol), whereas plots (B, C) have additional adjustments for HbA1c, fasting glucose and fasting insulin (model 2). Residuals were calculated from linear
regression model (formula: T2D statusBmetabolite concentrationþmodel 2). For further information, see Supplementary Table S4.
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adjusted model 2, the area under the receiver-operating-
characteristic curves (AUC) increased 2.6% (P¼ 0.015) and
1% (P¼ 0.058) for IGTand T2D, respectively (Supplementary
Figure S2; Supplementary Table S7). Thus, this provides an
improved prediction of IGT and T2D as compared with T2D
risk indicators.
Table III Odds ratios (ORs) and P-values in five pairwise comparisons with two adjusted models in the KORA S4
Metabolite Model 1 Model 2
OR (95% CI), per s.d. P-value OR (95% CI), per s.d. P-value
238 IGT versus 866 NGT
Glycine 0.65 (0.53–0.78) 5.6E-06 0.67 (0.54–0.81) 8.6E-05
LPC (18:2) 0.58 (0.47–0.7) 1.3E-07 0.58 (0.46–0.72) 2.1E-06
C2 1.37 (1.18–1.59) 3.8E-05 1.38 (1.16–1.64) 2.4E-04
91 dT2D versus 866 NGT
Glycine 0.47 (0.33–0.65) 1.1E-05 0.44 (0.22–0.83) 1.6E-02
LPC (18:2) 0.62 (0.44–0.85) 4.1E-03 0.61 (0.32–1.07) 1.1E-01
C2 1.17 (0.94–1.45) 1.5E-01 1.71 (1.14–2.52) 6.8E-03
91 dT2D versus 234 IGT
Glycine 0.81 (0.61–1.07) 1.5E-01 0.76 (0.51–1.1) 1.6E-01
LPC (18:2) 0.91 (0.69–1.19) 4.8E-01 0.84 (0.57–1.22) 3.7E-01
C2 0.93 (0.71–1.2) 5.9E-01 1.27 (0.87–1.86) 2.2E-01
102 i-IFG versus 866 NGT
Glycine 0.75 (0.57–0.98) 3.9E-02 0.62a 1.0Eþ 00
LPC (18:2) 0.99 (0.77–1.26) 9.6E-01 0.79a 1.0Eþ 00
C2 1.2 (0.99–1.46) 5.9E-02 0.18a 1.0Eþ 00
91 dT2D versus 102 i-IFG
Glycine 0.62 (0.43–0.87) 7.8E-03 0.62 (0.4–0.93) 2.5E-02
LPC (18:2) 0.62 (0.43–0.89) 1.1E-02 0.54 (0.33–0.84) 8.9E-03
C2 0.92 (0.66–1.27) 6.2E-01 1.23 (0.82–1.85) 3.1E-01
ORs were calculated with multivariate logistic regression analysis with adjustment for age, sex, BMI, physical activity, alcohol intake, smoking, systolic BP and HDL
cholesterol in model 1; model 2 includes those variable in model 1 plus HbA1c, fasting glucose and fasting insulin. CI denotes confidence interval.
aFasting glucose values were added as co-variants to the model 2, resulting in a perfect separation between i-IFG and NGT.
Table IV Prediction of IGTand T2D in the KORA cohort
Model Glycine LPC (18:2) C2 Glycine, LPC (18:2), C2
(A) Metabolite as continuous variable (n¼ 589)
Per s.d. 0.75 (0.58–0.95) 0.72 (0.54–0.93) 0.92 (0.73–1.14) 0.36 (0.20–0.67)
P 0.02 0.02 0.50 0.001
(B) Metabolite as categorical variable (n¼ 589)
First quartile 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
Second quartile 1.0 (0.80–1.46) 0.96 (0.73–1.27) 0.89 (0.66–1.23) 0.54 (0.30–0.97)
Third quartile 1.0 (0.74–1.34) 0.71 (0.51–0.99) 0.93 (0.69–1.26) 0.66 (0.37–1.18)
Fourth quartile 0.78 (0.55–1.06) 0.78 (0.54–1.12) 0.99 (0.73–1.35) 0.36 (0.19–0.69)
P for trend 0.06 0.05 0.79 0.0082
(C) Metabolite as continuous variable (n¼ 876)
Per s.d. 0.73 (0.55–0.97) 0.70 (0.51–0.94) 0.94 (0.74–1.18) 0.39 (0.21–0.71)
P 0.04 0.02 0.59 0.0002
(D) Metabolite as categorical variable (n¼ 876)
1st quartile 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
2nd quartile 0.87 (0.71–1.07) 0.95 (0.77–1.17) 1.05 (0.85–1.31) 0.50 (0.33–0.76)
3rd quartile 0.82 (0.67–1.01) 0.70 (0.56–0.88) 0.97 (0.78–1.19) 0.57 (0.38–0.88)
4th quartile 0.67 (0.54–0.84) 0.68 (0.54–0.88) 1.21 (0.98–1.50) 0.33 (0.21–0.52)
P for trend 0.00061 0.00021 0.19 1.8E 05
(E) Linear regression (n¼ 843)
b Estimatesa (95% CI)  2.47 ( 4.64,  0.29)  4.57 ( 6.90,  2.24) 1.02 ( 1.11, 3.15)  4.23 ( 6.52,  2.31)
P 0.026 0.00013 0.59 8.8E 05
Odds ratios (ORs, 95% confidence intervals) and P-values of multivariate logistic regression results are shown in (A) and (B) for IGT and in (C) and (D) for T2D,
respectively, whereas b estimates and P-values from linear regression analysis betweenmetabolite concentration in baseline KORA S4 and 2-h glucose values in follow-
up KORA F4 are shown in (E). All models were adjusted for age, sex, BMI, physical activity, alcohol intake, smoking, systolic BP and HDL cholesterol.
ab Estimate indicates the future difference in the glucose tolerance corresponding to the one s.d. differences in the normalized baseline metabolite concentration.
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Baseline metabolite concentrations correlate with
future glucose tolerance
We next investigated the associations between baseline
metabolite concentrations and follow-up 2-h glucose values
after an oral glucose tolerance test. Consistent results were
observed for the three metabolites: glycine and LPC (18:2), but
not acetylcarnitine C2 levels, were found to be significantly
associated, indicating that glycine and LPC (18:2) predict
glucose tolerance. Moreover, the three metabolites (glycine,
LPC (18:2) and C2) revealed high significance even in the fully
adjusted model 2 in the cross-sectional KORA S4 cohort
(Supplementary Table S8). As expected, a very significant
association (P¼ 1.510 22) was observed for hexose H1 in
model 1, while no significance (P¼ 0.12) was observed for it in
the fully adjusted model 2 (Supplementary Table S8).
Prospective population-based versus nested
case–control designs
To investigate the predict value of the five branched-chain and
aromatic amino acids (isoleucine, leucine, valine, tyrosine and
phenylalanine) (Wang et al, 2011) in our study, we correlated
the baseline metabolite concentrations with follow-up 2-h
glucose values. We found none of them to be associated
significantly, indicating that the five amino acids cannot
predict risk of IGT (b estimates and P-values are shown in
Supplementary Table S9). Furthermore, none of these five
amino acids showed associations with 2-h glucose values in
the cross-sectional KORA S4 study (Supplementary Table S8).
To replicate the identified five branched-chain and aromatic
amino acids (Wang et al, 2011), we matched our baseline
samples to the 91 incident T2D using the same method
described previously (Wang et al, 2011). We replicated four out
of the five branched-chain and aromatic amino acids
(characteristics of the case–control and non-T2D samples are
shown in Supplementary Table S10; ORs and P-values are
given in Supplementary Table S11). As expected, the three
identified IGT-specific metabolites did not significantly differ
between the matched case control samples, because the
selected controls were enriched with individuals accompanied
by high-risk features such as obesity and elevated fasting
glucose as described by Wang et al (2011). In fact, the 91
matched controls include about 50% pre-diabetes individuals,
which is significantly higher than the general population
(about 15%).
Replication in the cross-sectional EPIC-Potsdam
cohort
Metabolomics data from serum samples of a randomly drawn
EPIC-Potsdam subcohort (n¼ 2500) were used for replication.
Glycine (OR¼ 0.60 (0.47–0.77), P¼ 7.410 5) and LPC
(18:2) (OR¼ 0.79 (0.63–0.98), P¼ 0.037) were replicated
when 133 T2D patients were compared with 1253 individuals
with NGT at baseline (Supplementary Table S12). However,
acetylcarnitine C2 (OR¼ 0.98 (0.81–1.19), P¼ 0.858) could
not be replicated when T2D patients were compared with NGT
individuals, since the IGT participants were not available in
the data set. The absolute levels of these three metabolites
were in a similar range, with only slight differences that were
due probably to the differences of the two cohorts or to
potential batch effects of metabolomics measurements
(Supplementary Tables S12 and S15). Thus, these data
therefore provide an independent validation of the metabo-
lomics study.
Metabolite–protein interaction networks confirmed
by transcription levels
To investigate the underlying molecular mechanism for the
three identified IGT metabolites, we studied their associations
with T2D-related genes by analyzing protein-metabolite
interaction networks (Wishart et al, 2009; Szklarczyk et al,
2011). In all, 7 out of the 46 known T2D-related genes (PPARG,
TCF7L2,HNF1A, GCK, IGF1, IRS1 and IDE) were linked to these
metabolites through related enzymes or proteins (Figure 3A;
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Figure 3 Three candidate metabolites for IGT associated with seven T2D-related genes. (A) Metabolites (white), enzymes (yellow), pathway-related proteins (gray)
and T2D-related genes (blue) are represented with ellipses, rectangles, polygons and rounded rectangles, respectively. Arrows next to the ellipses and rectangles
indicate altered metabolite concentrations in persons with IGT as compared with NGT, and enzyme activities in individuals with IGT. The 21 connections between
metabolites, enzymes, pathway-related proteins and T2D-related genes were divided after visual inspections into four categories: physical interaction (purple solid line),
transcription (blue dash line), signaling regulation (orange dash line) and same pathway (gray dot and dash line). The activation or inhibition is indicated. For further
information, see Supplementary Table S12. (B) Log-transformed gene expression results of the probes of CAC, CrAT, ALAS-H and cPLA2 in 383 individuals with NGT,
104 with IGT and 26 patients with dT2D are shown from cross-sectional analysis of the KORA S4 survey. The P-values were adjusted for sex, age, BMI, physical activity,
alcohol intake, smoking, systolic BP, HDL cholesterol, HbA1c and fasting glucose when IGT individuals were compared with NGT participants.
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the list of 46 genes is shown in Supplementary Table S13). To
validate the networks, the links between metabolites,
enzymes, pathway-related proteins and T2D-related genes
were manually checked for biochemical relevance and
classified into four groups: signaling regulation, transcription,
physical interaction and the same pathway (Supplementary
Table S14).
Gene expression analysis in whole-blood samples of
participants from the KORA S4 revealed significant variations
(P-values ranging from 9.410 3 to 1.110 6) of transcript
levels of four enzymes, namely, carnitine/acylcarnitine
translocase (CAC), carnitine acetyltransferase (CrAT),
5-aminolevulinate synthase 1 (ALAS-H) and cytosolic phos-
pholipase A2 (cPLA2), which are known to be strongly
associated with the levels of the three metabolites
(Figure 3B). The clear relationship between changes in
metabolites and transcription levels of associated enzymes
strongly suggests that these metabolites are functionally
associated with T2D genes in established pathways.
Discussion
Using a cross-sectional approach (KORA S4, F4), we analyzed
140 metabolites and identified three (glycine, LPC (18:2) and
C2) which are IGT-specific metabolites with high statistical
significance. Notably, these three metabolites are distinct from
the currently known T2D risk indicators (e.g., age, BMI,
systolic BP, HDL cholesterol, HbA1c, fasting glucose and
fasting insulin). A prospective analysis (KORA S4-F4) shows
that low levels of glycine and LPC at baseline predict the risks
of developing IGT and/or T2D. Glycine and LPC especially
were shown to be strong predictors of glucose tolerance, even
7 years before disease onset. Moreover, those two metabolites
were independently replicated in the EPIC-Potsdam cross-
sectional study. Finally, based on our analysis of interaction
networks, and supported by gene expression profiles, we
found that seven T2D-related genes are functionally associated
with the three IGT candidate metabolites.
Different study designs reveal progression of IGT
and T2D
From a methodological point of view, our study is unique with
respect to the large sample sizes and the availability of
metabolomics data from two time points. This allowed us to
compare results generated with cross-sectional and prospec-
tive approaches directly, as well as with results from
prospective population-based cohort and nested case–control
designs. We found that individuals with IGT have elevated
concentrations of the acetylcarnitine C2 as compared with
NGT individuals only in the cross-sectional study, whereas C2
was unable to predict IGT and T2D 7 years before the disease
onset. We speculate that the acetylcarnitine C2 might be an
event with a quick effect.
Our analysis could replicate four out of the five branched-
chain and aromatic amino acids recently reported to be
predictors of T2D using nested/selected case–control samples
(Wang et al, 2011). However, the population-based prospective
study employed in our study revealed that these five amino
acids are in fact not associated with future 2-h glucose values.
It should be taken into account, however, that more pre-
diabetes individuals (B50%) were in the control group of that
study design, and that these markers were unable to be
extended to the general population (with only 0.4% improve-
ment from the T2D risk indicators as reported in the
Framingham Offspring Study) (Wang et al, 2011). Most likely,
changes in these amino acids happen at a later stage in the
development of T2D (e.g., from IGT to T2D); indeed, similar
phenomenon was also observed in our study (Supplementary
Figure S1D). In contrast, we found that combined glycine, LPC
(18:2) and C2 have 2.6 and 1% increment in predicting IGTand
T2D in addition to the common risk indicators of T2D. This
suggests they are better candidate for early biomarkers, and
specifically from NGT to IGT, than the five amino acids.
IFG and IGT should be considered as two different
phenotypes
By definition (WHO, 1999; ADA, 2010), individuals with IFG or
IGT or both are considered as pre-diabetics. Yet we observed
different behaviors regarding the change of the metabolite
panel fromNGT to i-IFG or to IGT, indicating that i-IFG and IGT
are two different phenotypes. For future studies, we therefore
suggest separating IFG from IGT.
Glycine
The observed decrease in the serum concentration of glycine in
individuals with IGT and dT2D may result from insulin
resistance (Pontiroli et al, 2004). It was already reported that
insulin represses ALAS-H expression (Phillips and Kushner,
2005). As insulin sensitivity progressively decreases during
diabetes development (McGarry, 2002; Stumvoll et al, 2005;
Faerch et al, 2009; Tabak et al, 2009), it is expected that the
expression levels of the enzyme increase in individuals with
IGT and dT2D, since ALAS-H catalyzes the condensation of
glycine and succinyl-CoA into 5-aminolevulinic acid (Bishop,
1990). This may explain our observation that glycine was
lower in both individuals with IGT and those with dT2D.
However, the level of fasting insulin in IGTand T2D individuals
was higher than in NGT participants in the KORA S4 study,
suggesting that yet undetected pathways may also play roles
here.
Acetylcarnitine C2
Acetylcarnitine is produced by the mitochondrial matrix
enzyme, CrAT, from carnitine and acetyl-CoA, a molecule that
is a product of both fatty acid b-oxidation and glucose
oxidation and can be used by the citric acid cycle for energy
generation. We observed higher transcriptional level of CrAT
in individuals with IGT and T2D, most probably due to an
activation of the peroxisome proliferator activated receptor
alpha (PPAR-a) pathway in peroxisomes (Horie et al, 1981).
Higher expression of CrATwould explain the elevated levels of
acetylcarnitine C2 in IGT individuals. Although it is not clear if
mitochondrial CrAT is overexpressed when there is increased
fatty acid b-oxidation (e.g., in diabetes; Noland et al, 2009), it
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is expected that additional acetylcarnitine will be formed by
CrAT due to increased substrate availability (acetyl-CoA),
thereby releasing pyruvate dehydrogenase inhibition by
acetyl-CoA and stimulating glucose uptake and oxidation.
An increase of acylcarnitines, and in particular of acetylcarni-
tine C2, is a hallmark in diabetic people (Adams et al, 2009).
Cellular lipid levels are increased in humans with IGTor overt
T2D who also may have altered mitochondrial function
(Morino et al, 2005; Szendroedi et al, 2007). Together, these
findings reflect an important role of increased cellular lipid
metabolites and impaired mitochondrial b-oxidation in the
development of insulin resistance (McGarry, 2002; Szendroedi
et al, 2007; Koves et al, 2008).
LPC (18:2)
In our study, individuals with IGTand dT2D had lower cPLA2
transcription levels, suggesting reduced cPLA2 activity. As a
result, a concomitant decrease in the concentration of
arachidonic acid (AA), a product of cPLA2 activity, is
expected. AA has been shown to inhibit glucose uptake by
adipocytes (Malipa et al, 2008) in a mechanism that is
probably insulin independent and that involves the GLUT-1
transporter. Therefore, our findings may point to regulatory
effects in individuals with IGT, since the inhibition of AA
production would result in an increased glucose uptake.
Limitations
While our metabolite profiles provide a snapshot of human
metabolism, more detailed metabolic profile follow-ups, with
longer time spans and more time points, are necessary to
further evaluate the development of the novel biomarkers.
Moreover, the influence from long-term dietary habits should
not be ignored, even though we used only serum from fasting
individuals (Altmaier et al, 2011; Primrose et al, 2011).
Furthermore, additional tissue samples (e.g., muscle and
adipocytes) and experimental approaches are needed to
characterize the causal pathways in detail.
Conclusions
Three novel metabolites, glycine, LPC (18:2) and C2, were
identified as pre-diabetes-specific markers. Their changes
might precede other branched-chain and aromatic amino
acids markers in the progression of T2D. Combined levels of
glycine, LPC (18:2) and C2 can predict risk not only for IGT but
also for T2D. Targeting the pathways that involve these newly
proposed potential biomarkers would help to take preventive
steps against T2D at an earlier stage.
Materials and methods
Ethics statement
Written informed consent was obtained from each KORA and EPIC-
Potsdam participant. The KORA and EPIC-Potsdam studies were
approved by the ethics committee of the Bavarian Medical Association
and the Medical Society of the State of Brandenburg, respectively.
Sample source and classification
The KORA surveys are population-based studies conducted in the city
of Augsburg and the surrounding towns and villages (Holle et al, 2005;
Wichmann et al, 2005). KORA is a research platform in the field of
epidemiology, health economics and health-care research. Four
surveys were conducted with 18 079 participants recruited from 1984
to 2001. The S4 consists of 4261 individuals (aged 25–74 years)
examined from 1999 to 2001. From 2006 to 2008, 3080 participants
(with an age range of 32–81) took part in an F4 survey. Ascertainments
of anthropometric measurements and personal interviews, as well as
laboratory measurements of persons, from the KORA S4/F4 have been
described elsewhere (Rathmann et al, 2009; Meisinger et al, 2010;
Jourdan et al, 2012).
Sampling
In the KORA cohort, blood was drawn into S-Monovettes serum tubes
(SARSTEDTAG & Co., Nu¨mbrecht, Germany) in the morning between
0800 and 1030h after at least 8 h of fasting. Tubes were gently inverted
twice, followed by 30min resting at room temperature, to obtain
complete coagulation. For serum collection, blood was centrifuged at
2750 g at 151C for 10min. Serumwas filled into synthetic straws,which
were stored in liquid nitrogen until the metabolic analyses were
conducted.
Metabolite measurements and exclusion of
metabolites
For the KORA S4 survey, the targeted metabolomics approach was
based on measurements with the AbsoluteIDQt p180 kit (BIOCRATES
Life Sciences AG, Innsbruck, Austria). This method allows simulta-
neous quantification of 188 metabolites using liquid chromatography
and flow injection analysis–mass spectrometry. The assay procedures
have been described previously in detail (Illig et al, 2010; Ro¨misch-
Margl et al, 2011). For each kit plate, five references (human plasma
pooledmaterial, Seralab) and three zero samples (PBS)weremeasured
in addition to the KORA samples. To ensure data quality, each
metabolite had tomeet two criteria: (1) the coefficient of variance (CV)
for the metabolite in the total 110 reference samples had to be smaller
than 25%. In total, seven outliers were removed because their
concentrations were larger than the mean plus 5 s.d.; (2) 50% of
all measured sample concentrations for the metabolite should be
above the limit of detection (LOD), which is defined as 3 median of
the three zero samples. In total, 140 metabolites passed the quality
controls (Supplementary Table S15): one hexose (H1), 21 acylcarni-
tines, 21 amino acids, 8 biogenic amines, 13 sphingomyelins (SMs), 33
diacyl (aa) phosphatidylcholines (PCs), 35 acyl-alkyl (ae) PCs and 8
lysoPCs. Concentrations of all analyzed metabolites are reported
in mM.
Measurements of the 3080 KORA F4 samples and the involved
cleaning procedure have already been described in detail (Mittelstrass
et al, 2011; Yu et al, 2012).
Gene expression analysis
Peripheral blood was drawn under fasting conditions from 599 KORA
S4 individuals at the same time as the serum samples used for
metabolic profiling were prepared. Blood samples were collected
directly in PAXgene (TM) Blood RNA tubes (PreAnalytiX). The RNA
extraction was performed using the PAXgene Blood miRNA kit
(PreAnalytiX). Purity and integrity of RNA was assessed on the
Bioanalyzer (Agilent) with the 6000 Nano LabChip reagent set
(Agilent). In all, 500ng of RNA was reverse-transcribed into cRNA
and biotin-UTP labeled, using the Illumina TotalPrep-96 RNA
Amplification Kit (Ambion). In all, 3000 ng of cRNA was hybridized
to the Illumina HumanHT-12 v3 Expression BeadChip. Chips were
washed, detected and scanned according to manufacturer’s instruc-
tions. Raw data were exported from the Illumina ‘GenomeStudio’
Software to R. The data were converted into logarithmic scores and
normalized using the quantile method (Bolstad et al, 2003). The
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sample sets comprised 383 individuals with NGT, 104 with IGTand 26
with dT2D. The known T2D individuals were removed as had been
done for the metabolomics analysis.
Data availability
Metabolite concentrations of Glycine, LPC (18:2) and C2 with T2D
status in the KORA S4 and F4 are provided (Supplementary Table S16).
Additional data from the KORA S4 and F4 studies, including the
metabolite concentrations and the gene expression with clinical
phenotypes used in this study, are available upon request from
KORA-gen (http://epi.helmholtz-muenchen.de/kora-gen). Requests
should be sent to kora-gen@helmholtz-muenchen.de and are subject
to approval by the KORA board to ensure that appropriate condi-
tions are met to preserve patient privacy. Formal collaboration and
co-authorship with members of the KORA study is not an automatic
condition to obtain access to the data published in the present paper.
More general information about KORA, including S4 and F4 study design
and clinical variables, can be found at http://epi.helmholtz-muenchen.
de/kora-gen/seiten/variablen_e.php and http:/helmholtz-muenchen.de/
en/kora-en/information-for-scientists/current-kora-studies.
Statistical analysis
Calculations were performed under the R statistical environment
(http://www.r-project.org/).
Multivariate logistic regression and linear
regression
In multivariate logistic regression analysis, ORs for single metabolites
were calculated between two groups. The concentration of each
metabolite was scaled to have a mean of zero and an s.d. of one; thus,
all reported OR values correspond to the change per s.d. of metabolite
concentration. Various T2D risk factors were added to the logistic
regression analysis as covariates. To handle false discovery rates from
multiple comparisons, the cutoff point for significance was calculated
according to the Bonferroni correction, at a level of 3.610 4 (for a
total use of 140 metabolites at the 5% level). Because the metabolites
were correlated within well-defined biological groups (e.g., 8 lysoPCs,
33 diacyl PCs, 35 acyl-alkyl PCs and 13 SMs), this correction was
conservative.
Additionally, the categorized metabolite concentrations and com-
bined scores (see below) were analyzed, and the ORs were calculated
across quartiles. To test the trend across quartiles, we assigned all
individuals either the median value of the concentrations or the
combined scores, and obtained the P-values using the same regression
model.
For linear regression analyses, b estimates were calculated from the
concentration of each metabolite and the 2-h glucose value. The
concentration of eachmetabolite was log-transformed and normalized
to have a mean of zero and an s.d. of one. Various risk factors in the
logistic regressionwere added as covariates, and the same significance
level (3.610 4) was adopted.
Combination of metabolites
To obtain the combined scores of metabolites, the scaled metabolite
concentrations (mean¼ 0, s.d.¼ 1) were first modeled with multi-
variate logistic regression containing all confounding variables. The
coefficients of these metabolites from the model were then used to
calculate a weighted sum for each individual. In accordance with the
decreasing trend of glycine and LPC (18:2), we inverted these values as
the combined scores.
Residuals of metabolite concentrations
To avoid the influence of other confounding factors when plotting the
concentration of metabolites, we used the residuals from a linear
regression model. Metabolite concentrations were log-transformed
and scaled (mean¼ 0, s.d.¼ 1), and the residuals were then deduced
from the linear regression that included the corresponding confound-
ing factors.
Random forest, stepwise selection methods and
candidate biomarker selection
To select candidate biomarkers, we applied two additional methods:
the random forest selection (Breiman, 2001) and the stepwise
selection, which assess the metabolites as a group.
Between two groups, the supervised classification method of
random forest was first used to select the metabolites among the 30
highest ranking variables of importance score, allowing the best
separation of the individuals fromdifferent groups. T2D risk indicators
were also included in this method with all the metabolites.
We further selected the metabolites using stepwise selection on the
logistic regression model. Metabolites with significantly different
concentrations between the compared groups in logistic regression,
and which were also selected using random forest, were used in this
model alongwith all the risk indicators. Akaike’s Information Criterion
(AIC) was used to evaluate the performance of these subsets of
metabolites used in the models. The model with minimal AIC was
chosen. The AUC was used to evaluate the models.
Network analysis
Metabolite–protein interactions from the Human Metabolome Data-
base (HMDB; Wishart et al, 2009) and protein–protein interactions in
the Search Tool for the Retrieval of Interacting Genes/Proteins
(STRING; Szklarczyk et al, 2011) were used to construct a network
containing relationships between metabolites, enzymes, other pro-
teins and T2D-related genes. The candidate metabolites were assigned
to HMDB IDs using the metaP-Server (Kastenmuller et al, 2011), and
their associated enzymes were derived according to the annotations
provided by HMDB. These enzymes were connected to the 46 T2D-
related genes (considered at that point), allowing for 1 intermediate
protein (other proteins) through STRINGprotein functional interaction
and optimized by eliminating edges with a STRING score ofo0.7 and
undirected paths. The subnetworks were connected by the shortest
path from metabolites to T2D-related genes.
Replication
The EPIC-Postdam is part of the multicenter EPIC study (Boeing et al,
1999; Riboli et al, 2002). It was drawn from the general adult
population in Potsdam and surrounding areas and consists of 27 548
participants recruited from 1994 to 1998 (Boeing et al, 1999). At
baseline, participants underwent anthropometric and BP measure-
ments, completed an interview on prevalent diseases, a questionnaire
on socioeconomic and lifestyle factors and submitted a validated food
frequency questionnaire. Follow-up questionnaires were administered
every 2–3 years (Bergmann et al, 1999).
From the EPIC-Potsdam population, a substudy of 2500 participants
was randomly selected from all participants who had provided blood
samples at baseline (n¼ 26 444). The substudy had a limited number
of fasting samples available. Therefore, non-fasting samples were also
considered. Out of the substudy, 814 participants were excluded
because of missing information on relevant covariates or missing
fasting samples. Individuals with NGT and T2D were determined
according to HbA1c categories defined by the American Diabetes
Association in 2010 (ADA, 2010).
In the EPIC-Potsdam study, 30ml of blood was drawn by qualified
medical staff during the baseline examination, immediately fractio-
nated into serum, plasma, buffy coat and erythrocytes and aliquoted
into straws. The blood samples were stored in liquid nitrogen
(at  1961C) until the metabolic analyses.
Metabolite measurements for the EPIC-Potsdam samples were
performed using the same kit and the same method as for the KORA
F4 samples (Floegel et al, 2011).
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Calculations were performed using the Statistical Analysis System
(SAS), Version 9.2 (SAS Institute, Inc., Cary, NC, USA).
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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